-
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
Increased nuchal translucency with normal karyotype.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1005-21. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5.